CD4/CD8 ratio in apheresis, EOP 19-28z transduced T cells, and blood samples after infusion
| Patient ID . | Apheresis . | EOP 19-28z T cells . | 19-28z T cells after infusion . | |
|---|---|---|---|---|
| CD4/CD8 . | CD4+CD28+/CD8+CD28+ . | CD4/CD8 . | CD4/CD8 (time after infusion) . | |
| CLL-1 | 2.4 | 2.4 | 18.8 | NA |
| CLL-2 | 0.3 | 0.3 | 19.2 | NA |
| CLL-3 | 3.5 | 6.8 | 11.6 | NA |
| CLL-4 | 0.5 | 4.0 | 141.4 | 70.4 (1 h); 33.5 (24 h) |
| CLL-5 | 0.8 | 1.0 | 7.3 | NA |
| CLL-6 | 1.5 | 2.3 | 3.8 | NA |
| CLL-7 | 2.5 | 7.0 | 2.5 | NA |
| CLL-8 | 4.5 | 6.0 | 10.1 | 19 (2 wk); 8.7 (4 wk); 8.8 (5 wk) |
| Mean ± SD | 2.0 ± 1.5 | 3.7 ± 2.6 | 10.5 ± 6.6* | NA |
| ALL-1 | 1.0 | 2.1 | 2.5 | 1.1 (8 d) |
| ALL-2 | 1.8 | 1.8 | 0.9 | NA |
| Patient ID . | Apheresis . | EOP 19-28z T cells . | 19-28z T cells after infusion . | |
|---|---|---|---|---|
| CD4/CD8 . | CD4+CD28+/CD8+CD28+ . | CD4/CD8 . | CD4/CD8 (time after infusion) . | |
| CLL-1 | 2.4 | 2.4 | 18.8 | NA |
| CLL-2 | 0.3 | 0.3 | 19.2 | NA |
| CLL-3 | 3.5 | 6.8 | 11.6 | NA |
| CLL-4 | 0.5 | 4.0 | 141.4 | 70.4 (1 h); 33.5 (24 h) |
| CLL-5 | 0.8 | 1.0 | 7.3 | NA |
| CLL-6 | 1.5 | 2.3 | 3.8 | NA |
| CLL-7 | 2.5 | 7.0 | 2.5 | NA |
| CLL-8 | 4.5 | 6.0 | 10.1 | 19 (2 wk); 8.7 (4 wk); 8.8 (5 wk) |
| Mean ± SD | 2.0 ± 1.5 | 3.7 ± 2.6 | 10.5 ± 6.6* | NA |
| ALL-1 | 1.0 | 2.1 | 2.5 | 1.1 (8 d) |
| ALL-2 | 1.8 | 1.8 | 0.9 | NA |
All phenotypes are analyzed by flow cytometry in 7-AAD− and CD45+ populations. All numbers are expressed in ratio of percentages of CD4/CD8 or CD4+CD28+/CD8+CD28+.
The average CD4/CD8 ratio excludes the CD4/CD8 ratio for CLL-4. With CLL-4, the average CD4/CD8 ratio is 26.8 ± 46.7. CLL-4 had the lowest CD8+CD28+ fraction (see supplemental Table 1).